A major research goal of the Arnaout Laboratory is to elucidate the structure and function of integrins, cell adhesion receptors that play vital roles in normal physiology and disease and use the derived information in structure-based design of new and safer anti-integrin drugs targeting heart disease, fibrosis, and cancer.
Other research interests include elucidating mechanisms underlying cyst formation in Autosomal Dominant Polycystic Kidney Disease, transcriptional regulation of hematopoiesis, mechanisms of kidney regeneration, and design of microfluidic dialysis devices.
Atomic structure of the integrin aVb3 in complex with macromolecular ligands
Structure-based design of novel anti-integrin therapeutics
EM structure of the leukocyte integrin CD11b/CD18 (aMb2)
Role of adaptor proteins in regulation of leukocyte integrins
Role of integrins in ischemia-reperfusion injury models
Mechanisms of cyst formation in Autosomal Dominant Polycystic Kidney Disease
Mechanisms of renal injury and regeneration
Development of microfluidic devices for dialysis
Transcriptional regulation of hematopoiesis
Research Positions
If you are interested in applying for a postdoctoral position, or are a Harvard PhD student interested in a laboratory rotation, please e-mail your CV (for student and postdoctoral) and reference letters (for postdoctoral) to: aarnaout1@mgh.harvard.edu
Dr. Arnaout was elected as member in the prestigious American Clinical and Climatological Association (ACCA) in Oct. 2019. Members of the ACCA comprise outstanding physicians selected on the basis of their leadership, scientific excellence, high level of integrity and professionalism. Active membership is limited to 250 physicians.
Dr. Arnaout has received the 2018 Homer W. Smith Award from the American Society of Nephrology (ASN). Read more on the Harvard Medical School website.
Dr. Arnaout has received the 2017 Kuwait Prize in Applied Medical Sciences from the KFAS. Read more in the MGH Awards and Honors newsletter.
We reached out to investigators at Massachusetts General Hospital and asked them to give us one science-backed action people can take to improve their heart health.
In a nationally representative of US adults with self-reported chronic liver disease (CLD), approximately 308,000 (6%) identified delaying medical care due to transportation barriers.
In this 12-month, placebo-controlled, randomized clinical trial of 26 well-treated persons with HIV without known CVD, eplerenone was associated with a significant reduction in arterial inflammation.
Arabs represent about 5% of the world population and are massively underrepresented in genomic studies worldwide, yet minimal efforts have been made to date to understand clinical utility of polygenic scores in this group.
1of
6
About the Nephrology Division
The Division of Nephrology at Massachusetts General Hospital is a leading provider of services for patients with kidney disease, including diagnosis and management of kidney diseases and medical management of renal transplantation.